A study reveals that a low-salt fasting-mimicking diet slows kidney disease progression in animal models and shows protective ...

In patients with chronic kidney disease, the loss of podocytes—part of the kidney's glomerular filtration barrier—causes irreversible disease progression. So far, physicians and researchers have found ...

SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated ...

数据表明， 早在治疗14天时即可观察到Fabhalta可减少C3G患者的蛋白尿，此结果具临床意义并持续至12个月。 在研究的开放标签阶段，切换至Fabhalta的受试者也表现出蛋白尿的减少。

Our medicines reach more than 250 million people worldwide. Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-Month results from the ...

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

Novartis (NOVN: VX) yesterday presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 glomerulopathy (C3G) ...

Clear or almost clear facial dermatitis was observed in 52% of patients treated with EBGLYSS by week 24. Credit: Pormezz/Shutterstock. Eli Lilly’s EBGLYSS has demonstrated improvement in skin ...

The results showed that patients with C3 glomerulopathy (C3G) treated with oral Fabhalta (iptacopan) alongside supportive care experienced clinically meaningful and sustained results over one year.

Kidney Week 2024 showing that patients with C3 glomerulopathy (C3G) treated with oral Fabhalta ® (iptacopan) in addition to supportive care experienced clinically meaningful, sustained results at ...